Download PDF

1. Company Snapshot

1.a. Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.The company operates through three segments: Generics, Specialty, and AvKARE.The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.


The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas.It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism.The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.


It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers.The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.It operates in the United States, India, Ireland, and internationally.


The company was formerly known as Atlas Holdings, Inc.and changed its name to Amneal Pharmaceuticals, Inc.in 2018.


Amneal Pharmaceuticals, Inc.was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Show Full description

1.b. Last Insights on AMRX

Amneal Pharmaceuticals' recent performance was negatively impacted by a Q4 2024 earnings miss, with a quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago, indicating a decline in profitability. The company's weak Q4 earnings were a significant negative driver, overshadowing its strong 2024 financials, which saw revenues up 17% year-over-year.

1.c. Company Highlights

2. Amneal Pharmaceuticals' Q3 2025 Earnings: Strong Growth Across Business Segments

Amneal Pharmaceuticals reported a robust Q3 2025, with total revenues growing 12% year over year to $785 million. The company's adjusted EBITDA was $160 million, up 1% year over year. Earnings per share (EPS) came in at $0.17, beating analyst estimates of $0.13. The strong financial performance was driven by growth across the company's three business segments, with Affordable Medicines revenue up 8% year over year to $461 million, and Specialty revenue also up 8% to $125 million.

Publication Date: Nov -29

📋 Highlights
  • Total Revenue Growth:: Q3 revenue increased 12% YoY to $785 million, with full-year guidance raised to $3 billion–$3.1 billion.
  • Affordable Medicines Segment:: Revenue grew 8% YoY to $461 million, driven by a portfolio of 280+ products and new launches like risperidone injectable.
  • Specialty Segment Performance:: Revenue rose 8% YoY to $125 million, fueled by CREXONT and UNITHROID, with authorized generics boosting RYTARY market share.
  • Financial Strength:: Adjusted EBITDA was $160 million (up 1% YoY), with full-year guidance of $675 million–$685 million and $300 million–$330 million operating cash flow.

Business Segment Performance

The Affordable Medicines segment continued to drive growth, with a broad portfolio of over 280 products. The Specialty segment also performed well, driven by products such as CREXONT and UNITHROID. As Chirag Patel noted, "Our growing portfolio is creating meaningful value for patients by expanding access and advancing standards of care, and for investors by driving consistent growth and margin expansion."

Guidance and Outlook

Amneal expects full-year revenues to be between $3 billion and $3.1 billion, with adjusted EBITDA between $675 million and $685 million. The company also expects continued strong operating cash flow between $300 million to $330 million this year. Analysts estimate revenue growth of 6.7% for next year, indicating a continued strong outlook for the company.

Valuation Metrics

Amneal's current valuation metrics indicate a relatively high price-to-earnings (P/E) ratio of 666.68, suggesting that the company's stock price may be sensitive to earnings growth. However, the price-to-sales (P/S) ratio is 1.34, which is relatively reasonable. The enterprise value-to-EBITDA (EV/EBITDA) ratio is 11.55, indicating a moderate level of leverage. The return on invested capital (ROIC) is 8.74%, and the return on equity (ROE) is 5.06%, indicating a relatively efficient use of capital.

Strategic Developments

Amneal is making strategic moves to drive growth, including its partnership with Metsera and its development of biosimilars. The company is also focused on operational excellence and is excited about the potential for its new product launches, including the Xolair biosimilar and the DHE autoinjector. With a solid balance sheet and a diversified portfolio, Amneal is well-positioned for continued growth and success.

3. NewsRoom

Card image cap

Amneal to Participate in Upcoming Investor Conferences

Dec -02

Source: globenewswire.com

Card image cap

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

Dec -02

Source: globenewswire.com

Card image cap

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Dec -01

Source: globenewswire.com

Card image cap

Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?

Nov -28

Source: fool.com

Card image cap

ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?

Nov -28

Source: zacks.com

Card image cap

Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs

Nov -21

Source: fool.com

Card image cap

Amneal Receives U.S. FDA Approval for Iohexol Injection

Nov -13

Source: globenewswire.com

Card image cap

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

Oct -30

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.10%)

6. Segments

Generics

Expected Growth: 5%

Amneal Pharmaceuticals' generics segment growth is driven by increasing demand for affordable medications, patent expirations of branded drugs, and strategic acquisitions. Additionally, the company's focus on vertical integration, cost savings, and investments in R&D and manufacturing capabilities have enabled it to capitalize on market opportunities, resulting in a 5% growth rate.

AvKARE

Expected Growth: 4%

AvKARE's 4% growth is driven by increasing demand for affordable generic medications, strategic partnerships, and expansion into new markets. Additionally, Amneal's vertical integration and cost-effective manufacturing capabilities enable AvKARE to offer competitive pricing, further fueling growth.

Specialty

Expected Growth: 7%

Amneal Pharmaceuticals' Specialty segment growth is driven by increasing demand for complex generics, successful product launches, and strategic partnerships. Additionally, the company's focus on niche therapeutic areas, such as CNS and infectious diseases, contributes to its growth. Furthermore, investments in R&D and manufacturing capabilities enable Amneal to capitalize on emerging opportunities in the specialty pharmaceutical market.

7. Detailed Products

Generic Pharmaceuticals

Amneal Pharmaceuticals offers a wide range of generic pharmaceuticals, including tablets, capsules, injectables, and ointments, covering various therapeutic areas such as cardiovascular, central nervous system, and infectious diseases.

Specialty Pharmaceuticals

Amneal's specialty pharmaceuticals segment focuses on complex and high-value products, including injectables, ophthalmics, and topical creams, targeting niche markets and underserved patient populations.

Biosimilars

Amneal's biosimilars segment develops and commercializes lower-cost, high-quality alternatives to branded biologics, offering affordable treatment options for patients with chronic diseases.

Over-the-Counter (OTC) Products

Amneal's OTC segment offers a range of consumer healthcare products, including pain relievers, allergy medications, and digestive health products.

Active Pharmaceutical Ingredients (APIs)

Amneal's API segment develops and supplies high-quality active pharmaceutical ingredients to pharmaceutical companies, enabling the production of finished dosage forms.

8. Amneal Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Amneal Pharmaceuticals, Inc. operates in a highly competitive industry with many substitutes available, but the company's focus on generic and specialty pharmaceuticals helps to mitigate this threat.

Bargaining Power Of Customers

Amneal Pharmaceuticals, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often essential to its customers, giving it an upper hand in negotiations.

Bargaining Power Of Suppliers

Amneal Pharmaceuticals, Inc. relies on a network of suppliers for raw materials and services. While the company has some bargaining power due to its size, suppliers may still exert some influence over prices and delivery terms.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs. This makes it difficult for new entrants to join the market.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players competing for market share. Amneal Pharmaceuticals, Inc. must continually innovate and invest in research and development to stay ahead of its competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 99.29%
Debt Cost 6.33%
Equity Weight 0.71%
Equity Cost 10.62%
WACC 6.36%
Leverage 13904.87%

11. Quality Control: Amneal Pharmaceuticals, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Intra-Cellular Therapies

A-Score: 5.3/10

Value: 6.0

Growth: 7.1

Quality: 5.1

Yield: 0.0

Momentum: 10.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Elanco Animal Health

A-Score: 4.6/10

Value: 3.9

Growth: 6.0

Quality: 5.1

Yield: 0.0

Momentum: 8.5

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Amneal Pharmaceuticals

A-Score: 4.4/10

Value: 3.9

Growth: 3.7

Quality: 6.0

Yield: 0.0

Momentum: 7.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Lantheus Holdings

A-Score: 4.2/10

Value: 5.8

Growth: 9.0

Quality: 7.9

Yield: 0.0

Momentum: 0.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Deciphera Pharmaceuticals

A-Score: 3.9/10

Value: 6.2

Growth: 6.1

Quality: 5.0

Yield: 0.0

Momentum: 5.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Catalent

A-Score: 3.0/10

Value: 3.2

Growth: 2.2

Quality: 1.8

Yield: 0.0

Momentum: 6.0

Volatility: 5.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

12.08$

Current Price

12.08$

Potential

-0.00%

Expected Cash-Flows